MarketCap
Facebook
X
Telegram
Cue Biopharma Income Statement 2025-2011 | CUE
Brief overview of financial results at Cue Biopharma
The comparison covers a five-year financial horizon. The revenue attributed to Cue Biopharma moved from 3.2 million dollars to 27.5 million dollars between the two endpoints. The five-year change reached +770.7%, while CAGR stood at 54.2%. Revenue growth reflects a pronounced phase of business expansion.
EBITDA was −44 million dollars at the beginning and −25.6 million dollars at the end of the period (+41.8%). Operating performance weakened relative to revenue. Comparing the endpoints gives EBITDA margins of −1394.4% and −93.2%. The increased EBITDA share is a positive sign.
Across the five years, the net result shifted from −$44.8 million to −$26.6 million. The loss reduction is constructive, but the recovery is incomplete.
The market value of the business moved from $388 million to $29.4 million, or −92.4%. The market is not yet fully reflecting the fundamental progress.
Summary assessment
The figures do not all move in the same direction. The financial profile benefits from sales growth, an improving EBITDA margin and improving net profitability. The most visible risks are limited operating profitability and declining capitalization. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Cue Biopharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
29.4 M | 51.3 M | 86.5 M | 108 M | 354 M | 388 M | 337 M | 101 M | 311 M | - | - | - | - | - | - |
Shares |
94.7 M | 56.3 M | 45.8 M | 35.6 M | 31.3 M | 28.7 M | 22 M | 20.1 M | 20.6 M | - | - | - | - | - | - |
Historical Prices |
0.31 | 0.91 | 1.89 | 3.04 | 11.3 | 12.5 | 15.9 | 4.7 | - | - | - | - | - | - | - |
Net Income |
-26.6 M | -40.7 M | -50.7 M | -53 M | -44.2 M | -44.8 M | -36.7 M | -39 M | -23.2 M | -7.66 M | -1.93 M | - | - | - | - |
Revenue |
27.5 M | 9.29 M | 5.49 M | 1.24 M | 14.9 M | 3.15 M | 3.46 M | 1.14 M | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | 3.15 M | - | - | - | - | - | - | - | - | - |
Operating Income |
-26.6 M | -41.5 M | -52.1 M | -53.2 M | -43.7 M | -45 M | -36.8 M | -38.7 M | -23.2 M | - | - | - | - | - | - |
Interest Expense |
100 K | 100 K | 100 K | 109 K | - | - | 64.1 K | 165 K | - | - | - | - | - | - | - |
EBITDA |
-25.6 M | -41.1 M | -51.6 M | -52.3 M | -42.5 M | -44 M | -31.6 M | -37.9 M | -22.8 M | -7.46 M | -1.88 M | - | - | - | - |
Operating Expenses |
54 M | 50.8 M | 57.6 M | 54.5 M | 58.7 M | 48.2 M | 40.2 M | 39.8 M | - | - | - | - | - | - | - |
General and Administrative Expenses |
16.2 M | 14.6 M | 16.7 M | 16.2 M | 17.3 M | 14.7 M | 12.7 M | 11.3 M | 4.33 M | 1.97 M | 425 K | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Cue Biopharma
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
4.81 M | 101 M | 95.5 M | 74.3 M | 61.8 M | 51.2 M | 50.2 M | 49.5 M | 47.2 M | 46.4 M | 44.8 M | 44.7 M | 43 M | 35.4 M | 35.4 M | 32.6 M | 32.2 M | 31.3 M | 31.2 M | 30.4 M | 30.4 M | 29.7 M | 28.2 M | 26.6 M | 26.6 M | 22.5 M | 20.8 M | 20.7 M | 20.7 M | 20.1 M | 20.1 M | 20.1 M | 19.5 M | 10.6 M | 10.6 M | 10.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-5.18 M | -7.45 M | -8.48 M | -12.3 M | - | -8.66 M | -10.2 M | -12.3 M | - | -11 M | -13.2 M | -13.1 M | - | -11 M | -13.2 M | -14.3 M | - | -13 M | -10.3 M | -12.5 M | - | -10 M | -10.8 M | -12.8 M | - | -6.99 M | -9.52 M | -11.3 M | - | -12.6 M | -7.3 M | -7.52 M | - | -5.03 M | -4.41 M | -3.35 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
5.69 M | 2.15 M | 2.95 M | 421 K | - | 3.34 M | 2.66 M | 1.72 M | - | 2.1 M | 1.38 M | 187 K | - | 68 K | 26 K | 1 M | - | 2.4 M | 2.74 M | 1.55 M | - | 704 K | 1.08 M | 900 K | - | 984 K | 1.06 M | 370 K | - | 449 K | 172 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-5.35 M | -7.6 M | -8.64 M | -12.3 M | - | -8.82 M | -10.4 M | -12.7 M | - | -11.4 M | -13.5 M | -13.4 M | - | -11 M | -13.1 M | -14.2 M | - | -13 M | -10.3 M | -12.5 M | - | -10.1 M | -10.9 M | -13 M | - | -7.09 M | -9.23 M | -11.4 M | - | -12.8 M | -7.47 M | -7.52 M | - | -5.03 M | -4.41 M | -3.35 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
100 K | -75 K | -45 K | -128 K | - | -188 K | -215 K | 33 K | - | -286 K | -232 K | 330 K | - | 33 K | 33 K | -25 K | - | - | - | - | - | -23 K | -25 K | -26 K | - | 5 K | 26 K | 46 K | - | 98 K | 2 K | -1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-4.79 M | -7.52 M | -8.54 M | -12.2 M | - | -8.72 M | -10.3 M | -12.6 M | - | -11.3 M | -13.4 M | -13.2 M | - | -10.8 M | -12.9 M | -13.9 M | - | -12.1 M | -10.1 M | -12.2 M | - | -9.33 M | -10.4 M | -12.7 M | - | -6.49 M | -8.82 M | -11.2 M | - | -12.6 M | -7.28 M | -7.36 M | - | -4.74 M | -4.24 M | -3.28 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
11 M | 9.74 M | 11.6 M | 12.7 M | - | 12.2 M | 13 M | 14.4 M | - | 13.5 M | 14.9 M | 13.6 M | - | 11.1 M | 13.1 M | 15.2 M | - | 15.4 M | 13 M | 14.1 M | - | 10.8 M | 12 M | 13.9 M | - | 8.08 M | 10.3 M | 11.8 M | - | 13.2 M | 7.64 M | 7.52 M | - | 5.03 M | 4.41 M | 3.35 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
4.15 M | 4.94 M | 3.68 M | 4.17 M | - | 2.87 M | 3.51 M | 4.19 M | - | 3.64 M | 4.25 M | 4.18 M | - | 3.53 M | 3.78 M | 5.16 M | - | 4.12 M | 4.28 M | 4.26 M | - | 3.32 M | 3.9 M | 3.99 M | - | 2.78 M | 3.42 M | 3.44 M | - | 2.9 M | 2.23 M | 1.7 M | - | 1.03 M | 996 K | 889 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Cue Biopharma (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Niderland
Irlanda
